Under the acquisition, DiscoveRx will add BioSeek’s BioMAP drug screening platform to its drug discovery solutions portfolio which includes GPCR, Kinase, and NHR assay solutions and KINOMEscan technology.
The BioMAP drug screening platform, which is based on cell-based disease models, generates predictive biological activity profiles for potential treatments.
DiscoveRx president and chief executive officer Pyare Khanna said the integration of BioSeek provides two new capabilities to the company.
"Expertise in primary cell disease models as well as a highly differentiated compound characterization service," Khanna added.
"These new capabilities further strengthen our position as a premier drug discovery solution provider that develops and commercializes high-value products and specialized services."